Deutsch
 
Hilfe Datenschutzhinweis Impressum
  DetailsucheBrowse

Datensatz

 
 
DownloadE-Mail
  Interferon-1a reduces increased interleukin-16 levels in multiple sclerosis patients

Nischwitz, S., Faber, H., Saemann, P. G., Domingues, H. S., Krishnamoorthy, G., Knop, M., et al. (2014). Interferon-1a reduces increased interleukin-16 levels in multiple sclerosis patients. ACTA NEUROLOGICA SCANDINAVICA, 130(1), 46-52. doi:10.1111/ane.12215.

Item is

Externe Referenzen

einblenden:

Urheber

einblenden:
ausblenden:
 Urheber:
Nischwitz, S.1, Autor           
Faber, H.1, Autor           
Saemann, P. G.2, Autor           
Domingues, H. S.3, Autor
Krishnamoorthy, G.3, Autor
Knop, M.1, Autor           
Müller-Sarnowski, F.2, Autor           
Yassouridis, A.2, Autor           
Weber, F.1, Autor           
Affiliations:
1Dept. Clinical Research, Max Planck Institute of Psychiatry, Max Planck Society, ou_2035296              
2Max Planck Institute of Psychiatry, Max Planck Society, ou_1607137              
3external, ou_persistent22              

Inhalt

einblenden:
ausblenden:
Schlagwörter: -
 Zusammenfassung: Objectives There is convergent evidence for an important role of interleukin-16 (IL-16) in the pathogenesis of multiple sclerosis (MS). IL-16 serves as a chemoattractant for different immune cells that are involved in developing lesions. Here, we compared IL-16 levels of MS patients and controls and addressed the long-term effect of IFN-, the most common immunomodulatory MS therapy, on IL-16 serum levels in MS patients over 2years. Beyond this, we analysed the expression of IL-16 in two CD4+ T-cell subsets, Th1 and Th17 cells, which are important autoimmune mediators and affected by IFN- treatment, derived from myelin-specific T-cell transgenic mice. Materials and methods IL-16 serum levels of 17 controls and of 16 MS patients before therapy and at months 1, 2, 3, 6, 9, 12 and 24 during IFN-1a therapy were determined by ELISA. MRI was performed before therapy, at months 12 and 24. IL-16 expression of in vitro differentiated murine myelin oligodendrocyte glycoprotein (MOG)-specific Th1 and Th17 cells was quantified by real-time PCR. Results Before therapy, MS patients showed significantly elevated IL-16 levels compared with controls irrespective of disease activity determined by MRI. Therapy with IFN-1a led to a significant linear decrease in IL-16 serum levels beginning after 2months. MOG-specific Th17 cells expressed more IL-16 than Th1 cells. Conclusions Reduction in increased IL-16 levels may be of relevance for the therapeutic effect of IFN-1a in MS. Easily accessible IL-16 serum levels hold a potential as biomarker of treatment efficacy in MS.

Details

einblenden:
ausblenden:
Sprache(n): eng - English
 Datum: 2014-07
 Publikationsstatus: Erschienen
 Seiten: -
 Ort, Verlag, Ausgabe: -
 Inhaltsverzeichnis: -
 Art der Begutachtung: -
 Identifikatoren: ISI: 000337633400008
DOI: 10.1111/ane.12215
 Art des Abschluß: -

Veranstaltung

einblenden:

Entscheidung

einblenden:

Projektinformation

einblenden:

Quelle 1

einblenden:
ausblenden:
Titel: ACTA NEUROLOGICA SCANDINAVICA
Genre der Quelle: Zeitschrift
 Urheber:
Affiliations:
Ort, Verlag, Ausgabe: Oxford, UK : John Wiley & Sons Ltd.
Seiten: - Band / Heft: 130 (1) Artikelnummer: - Start- / Endseite: 46 - 52 Identifikator: ISSN: 0001-6314